Actuate Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Phase 2
Withdrawn
- Conditions
- Salivary Gland CarcinomaAdenoid Cystic CarcinomaSalivary Gland CancerSalivary Gland Neoplasms
- Interventions
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2022-02-22
- Lead Sponsor
- Actuate Therapeutics Inc.
- Registration Number
- NCT04832438
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9-ING-41 in Pediatric Patients with Refractory Malignancies.
Phase 1
Recruiting
- Conditions
- Cancer PediatricPediatric CancerPediatric Brain TumorRefractory CancerRefractory TumorPediatric MeningiomaNeuroblastomaNeuroblastoma RecurrentRefractory NeoplasmPediatric Lymphoma
- Interventions
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Actuate Therapeutics Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT04239092
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Actuate 1901: 9-ING-41 in Myelofibrosis
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Actuate Therapeutics Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT04218071
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸Georgia Cancer Center, Augusta, Georgia, United States
9-ING-41 in Patients with Advanced Cancers
Phase 2
Active, not recruiting
- Conditions
- CancerPancreatic CancerPancreatic AdenocarcinomaNeoplasm, BreastNeoplasms PancreaticMalignanciesMalignancies MultipleBone CancerPancreatic NeoplasmsNeoplasm Metastasis
- Interventions
- Drug: Nab paclitaxel.Drug: Doxorubicin.Drug: Carboplatin.Drug: Paclitaxel.
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Actuate Therapeutics Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT03678883
- Locations
- 🇪🇸
Institut Catala d'Oncologia, Barcelona, Spain
🇪🇸Hospital Clinico U San Carlos (HSC), Madrid, Spain
🇪🇸START Madrid-HM CIOCC Hospital Universitario, Madrid, Spain
© Copyright 2025. All Rights Reserved by MedPath